LAG3 and neoplasm: The tumor-preventive effects primarily involved the suppression of regulatory T cells and a low level of T cell exhaustion in the periphery (PD1+), as well as in the spleen, identified by reduced numbers of LAG-3+ splenocytes in both treatment groups.